Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Natco Pharma

Stocks in news: Reliance Industries, Bank of Baroda, Power Grid, NATCO Pharma and JSW Infra

Indian equity markets closed largely unchanged on Friday, August 21, after a volatile trading session. Several companies, including Reliance Industries and Bank of Baroda, reported significant corporate developments. Power Grid Corporation and Jubilant Pharmova also announced key project wins and regulatory approvals. NATCO Pharma and Caplin Point Laboratories received observations…

The Economic Times

Dividend alert! Last day to buy Mazagon Dock, Natco Pharma and 13 other stocks for dividends. Do you own any?

Mazagon Dock Shipbuilders in April had announced that its board of directors have recommended a final dividend of Rs 4.62 per share for the financial year 2026. The company later fixed August 20 as the record date to determine the eligibility of shareholders set to receive the payment.

The Economic Times

Bonus, stock splits & dividends: Bandhan Bank, MGL, Mazagon Dock among nearly 100 stocks turning ex-record date this week

In the upcoming week, nearly one hundred companies have announced record dates for dividends, making it crucial for investors to hold shares prior to these dates for eligibility in corporate actions. Notably, companies like Bandhan Bank and LIC Housing Finance are part of this corporate movement, which includes dividend payments,…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Natco Pharma Q1 profit falls 57 pc to Rs 206.5 cr

Natco Pharma has reported a stark profit decline in the first quarter, largely driven by reduced sales of its leading cancer drug, lenalidomide. This led to a pronounced drop in consolidated revenues compared to the prior year. On a brighter note, the core business showed some positive growth, and total…

The Economic Times

Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tablets

Natco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent version of AstraZeneca’s Lynparza. The drug addresses a $1.4-billion U.S. market opportunity. The company will manufacture the product, while Alembic Pharmaceuticals will handle its U.S. commercialisation.

The Economic Times

Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn

Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of Lynparza. Alembic will distribute the product while NATCO Pharma will manufacture the tablets. The product addresses a significant market opportunity, estimated at USD 1.4…

The Economic Times

Stocks in news: TCS, Nalco, Maruti Suzuki, Natco Pharma, HFCL

Indian markets saw a significant decline on Wednesday, influenced by global factors. TCS anticipates modest profit growth amid client spending caution and wage pressures. Nalco and NLC India will form a joint venture for a power plant. HFCL plans substantial investment to boost optical fibre cable production capacity. Natco Pharma…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Natco Pharma to invest Rs 2,500 crore in South Africa expansion

Natco Pharma will invest nearly Rs 2,500 crore in South Africa. This includes Rs 1,400 crore for its local subsidiary. The company will also increase its stake in Adcock Ingram. This acquisition is valued at Rs 1,069 crore. The transaction aims to expand Natco's geographic footprint.

The Economic Times

Natco Pharma shares crash 15% after weak Q4 results; net profit tanks 34% YoY

Natco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins and lower annual earnings weighed on investor sentiment despite a one-time tax-related benefit recorded during the quarter and full financial year.

The Economic Times

U.S. FDA issues warning letter to Natco over facility near Hyderabad

Natco Pharma's Kothur facility near Hyderabad receives FDA warning letter over quality concerns, impacting product approvals.

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Cancer

25,224 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.